🔴 BreakingDrug approvalRSSYesterday
The FDA has approved Otarmeni, a new gene therapy treatment for genetic hearing loss. This is the first-of-its-kind treatment that uses a special virus to deliver healthy genes into the ear to help restore hearing. The approval was fast-tracked through a special FDA program that prioritizes treatments for serious diseases.
WHY IT MATTERSThis is the first gene therapy approved specifically for inherited hearing loss, offering a potential one-time treatment option for patients with certain genetic forms of deafness who previously had no curative options.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called SPK-10001 to treat Huntington's disease, a rare brain disorder that causes movement problems and cognitive decline. This early-stage study will check if the treatment is safe and whether it helps patients. About 53 people with Huntington's disease will participate in this trial, which is being run by Roche, a major pharmaceutical company.
WHY IT MATTERSThis is one of the first human trials of SPK-10001, a gene therapy specifically designed to target the genetic cause of Huntington's disease, offering hope for a disease that currently has no cure.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called BBP-812 to treat Canavan disease, a rare brain disorder that affects children. The therapy uses a modified virus to deliver a healthy copy of a gene that's missing or broken in people with this disease. This early-stage trial will check if the treatment is safe and whether it helps patients.
WHY IT MATTERSThis trial is now actively recruiting children with Canavan disease — if your child has been diagnosed, you may be eligible to participate in one of the first human tests of this gene therapy approach.
PolicyRSSApr 14
The FDA released new guidelines to help companies develop gene therapy treatments that use genome editing—a technology that can fix or change faulty genes. These guidelines explain what safety information and testing companies need to provide before the FDA will approve their treatments. This is meant to make it clearer and faster for companies to develop new gene therapies for patients with genetic diseases.
WHY IT MATTERSThis guidance establishes the regulatory pathway that will determine which genome editing therapies can reach patients, potentially accelerating approval timelines for rare genetic diseases currently lacking treatment options.
Clinical trialCLINICALTRIALSApr 14
Researchers tested a new gene therapy called ST-920 for Fabry disease in 36 patients. This treatment uses a modified virus to deliver instructions that help the body make an enzyme called alpha-galactosidase A, which people with Fabry disease don't produce enough of. The trial is now complete and tested whether different doses were safe and well-tolerated.
WHY IT MATTERSThis completed Phase 1/2 trial is the first human test of ST-920, meaning results could help determine if gene therapy can provide long-term relief for Fabry disease patients who currently require lifelong enzyme replacement infusions.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new treatment called Kresladi for a rare immune system disorder called Leukocyte Adhesion Deficiency Type I (LAD-I). This treatment works by using gene therapy, which means it fixes the faulty gene that causes the disease. This is the first gene therapy approved for this specific condition, giving patients with LAD-I a new treatment option.
WHY IT MATTERSPatients with severe LAD-I now have access to the first FDA-approved gene therapy for their condition, which could potentially offer a cure rather than just managing symptoms.
NewsPUBMEDMar 28
This is an editorial article that introduces a special collection of scientific papers about gene therapy for rare diseases. Gene therapy is a treatment that fixes or replaces faulty genes that cause disease. The editorial discusses how gene therapy is becoming an important treatment option for rare diseases that affect small numbers of people.
WHY IT MATTERSThis editorial highlights the growing momentum in gene therapy development for rare diseases, which means more treatment options may become available for conditions that previously had few or no approved therapies.